New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTCBRL, BCEI, VAR, MDCO, DKS, ALKS, ARQL, ARIAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Citigroup... Alkermes (ALKS) initiated with a Buy at Citigroup... ArQule (ARQL) initiated with a Buy at Citigroup... Bonanza Creek Energy (BCEI) initiated with a Buy at SunTrust... Dick's Sporting (DKS) initiated with a Market Perform at BMO Capital... The Medicines Co. (MDCO) initiated with a Neutral at Citigroup... Varian Medical (VAR) initiated with a Buy at Brean Capital... Cracker Barrel (CBRL) initiated with a Buy at CL King.
News For ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
10:25 EDTDKSOptions with decreasing implied volatility
Subscribe for More Information
07:40 EDTDKSDick's Sporting price target raised to $56 from $51 at Susquehanna
Subscribe for More Information
November 18, 2014
11:28 EDTDKSGoPro rises after company, shareholders file to sell 10.36M shares
Shares of GoPro (GRPO) are rising in early trade after the company filed to sell 10.36M shares of its stock on behalf of the company and its stockholders. WHAT'S NEW: GoPro announced in a prospectus that it is selling about 1.29M shares of class A common stock and that selling stockholders are selling 9.073M shares of class A common stock. The holders of the company's outstanding class B common stock will hold approximately 96.1% of the voting power following this offering, with its executive officers and directors and their affiliates holding approximately 65% and CEO Nicholas Woodman holding approximately 42.5% after his sale of about 4.08M shares of class A common stock in this offering, the company explained. GoPro estimated that it will receive net proceeds of $97.1M from the sale of class A shares, assuming a public offering price of $79.15 per share. The company said it expects to use the net proceeds of this offering for general corporate purposes including working capital, adding that it may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies or assets. "However, we have no present commitments or agreements to enter into any acquisitions or make any investments," GoPro noted. WHAT'S NOTABLE: On November 10, GoPro shares slipped after its CEO acknowledged he planned to sell some of his stake as part of this stock offering. In a regulatory filing at that time, the company shared an email message sent by Woodman to employees, in which he assured that he plans to be a "significant shareholder in GoPro for a long time." Additionally, on its earnings conference call this morning, Dick's Sporting Goods (DKS) management said it continues to be "extremely enthusiastic" about the electronics category, particularly wearables, GoPro cameras, and the Fitbit activity tracker. ANALYST OPINION: In a note to investors this morning, Pacific Crest said channel checks for high end GoPros are looking better than expected. The firm said it sees upside to the upcoming quarter for Ambarella (AMBA), which provides components used by GoPro in its cameras. Pacific Crest increased its price target on Ambarella shares to $55 from $47 and maintains its Outperform rating on the stock. PRICE ACTION: In morning trading, shares of GoPro rose 4.2% to $84.92, while Ambarella (AMBA) gained 5.8% to $51.60.
10:50 EDTDKSDick's Sporting says committed to returning cash to shareholders
Sees FY gross margin declining. Says not exiting golf, Golf Galaxy business.
10:17 EDTDKSDick's Sporting sees retail environment competitive, promotional
Subscribe for More Information
07:34 EDTDKSDick's Sporting sees FY14 EPS ex-items $2.75-$2.85, consensus $2.79
Subscribe for More Information
07:33 EDTDKSDick's Sporting sees Q4 EPS $1.18-$1.28, consensus $1.21
Sees Q4 consolidated same store sales to increase approximately 1%-3%. Q4 revenue consensus $2.12B.
07:32 EDTDKSDick's Sporting reports Q3 EPS 41c, consensus 41c
Reports Q3 revenue $1.53B, consensus $1.53B. Consolidated same store sales increased 1.1%, compared to the company's guidance of an approximate 1%-3% increase. Same store sales for DICK'S Sporting Goods increased 1.7%, while Golf Galaxy decreased 8.9%.
07:20 EDTARQLEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 17, 2014
15:27 EDTDKSDick's Sporting November 47 straddle priced for 7.1% move into Q3
Subscribe for More Information
15:16 EDTDKSNotable companies reporting before tomorrow's open
Subscribe for More Information
14:58 EDTDKSDick's Sporting technical comments before earnings
Subscribe for More Information
07:16 EDTALKSMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
November 13, 2014
12:39 EDTDKSDick's Sporting volatility elevated into Q3 and outlook
Subscribe for More Information
11:54 EDTALKSJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use